Eton Pharmaceuticals Launches IMPAVIDO Capsules, Adds Patient Support

What Happened
Eton Pharmaceuticals, Inc. (ETON) announced on September 28, 2026 that it has launched IMPAVIDO® (miltefosine) capsules. The company said it has integrated full Eton Cares patient support for the product, including a $0 co-pay program for eligible commercially insured patients and expanded patient assistance programs. The announcement was made via a press release attached to the Form 8-K (Exhibit 99.1).

Key Details

• Filing date: September 28, 2026 (Form 8-K, Item 8.01).
• Product: IMPAVIDO® (miltefosine) capsules — commercial launch announced.
• Patient support: Full Eton Cares integration with $0 co-pay for eligible commercially insured patients and expanded patient assistance programs.
• Disclosure: Announcement provided as a press release (Exhibit 99.1) in the 8-K.

Why It Matters
A commercial launch is a key step toward revenue generation and market uptake for a pharmaceutical product. The inclusion of $0 co-pay and expanded assistance can improve patient access and may help adoption among prescribers and patients, which investors should watch as potential drivers of future sales. The 8-K does not disclose sales, revenue projections, or financial results related to the launch; investors should monitor upcoming financial reports and company updates for measurable commercial performance.